In the extracellular milieu, eADO is generated starting from eATP via two ectoenzymes, CD39 and CD73, which are also upregulated in the tumor lesion, favoring cancer growth through eADO-mediated immune suppression (Allard et al., 2020; Battastini et al., 2021). The gene discussed is ENTPD1; the disease is neoplasm.